Monday, May 4, 2020 @ 12:00 am
Cytosurge's collaboration with Harvard's Wyss Institute for Biologically Inspired Engineering and the group of George Church will focus on developing multiplexed gene editing approaches using our FluidFM single-cell nano-injection technology that maintains cell viability and fitness.
Cytosurge collaborates with the Wyss Institute for Biologically Inspired Engineering at Harvard University. In this new research partnership they will investigate CRISPR-based approaches to more effectively introduce multiple edits into the genome of single cells, while minimizing CRISPR-related toxicity. This capability could become instrumental in driving forward diverse large-scale efforts such as the engineering of cell lines for pharmaceutical, clinical and biotechnological applications, transplantable immune-compatible pig organs, and the resurrection of extinct species.
“Cytosurge’s cell manipulation platform with its cell injection and sampling capabilities that themselves don’t harm cells offers us an entry point into this complex analysis and could help us dramatically expand the multiplexing potential of the CRISPR system longer-term", says George Church, Ph.D., Founding Core Faculty member at the Wyss Institute and Lead of its Synthetic Biology focus area.